Welcome to our dedicated page for HALOZYME THERAPEUTICS SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HALOZYME THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HALOZYME THERAPEUTICS's regulatory disclosures and financial reporting.
HALOZYME THERAPEUTICS, INC. director Mahesh Krishnan received equity awards consisting of common stock and stock options as part of the company’s director compensation program. He acquired 3,796 shares of common stock at no cash cost through a restricted stock unit grant.
He was also granted options to purchase 6,040 shares of common stock at an exercise price of $65.87 per share, expiring on May 5, 2036. Both the RSUs and options vest in full on the earlier of May 5, 2027 or the company’s next annual meeting of stockholders. After these grants, he directly holds 14,462 shares of common stock.
Halozyme Therapeutics director James Paul Lang received equity awards as part of the company’s director compensation program. He was granted 3,796 restricted stock units, each representing one share of common stock, bringing his direct common stock holdings to 4,685 shares.
Lang also received options to purchase 6,040 shares of common stock at an exercise price of $65.87 per share, expiring on May 5, 2036. Both the RSUs and options vest in full on the earlier of May 5, 2027 or the next annual stockholder meeting, with RSU settlement deferred until completion of his board service.
Henderson Jeffrey William reported acquisition or exercise transactions in this Form 4 filing.
HALOZYME THERAPEUTICS director Jeffrey William Henderson received equity compensation in the form of stock and options. He was granted 3,796 restricted stock units, each representing one share of common stock, and an option to purchase 6,040 shares at $65.87 per share.
The RSU and stock option grants are part of the company’s director compensation program. Both awards vest in full on the earlier of May 5, 2027 or the date of the company’s next annual meeting of stockholders. Following the grants, he directly holds 36,572 shares of common stock.
HALOZYME THERAPEUTICS, INC. director Barbara Gayle Duncan received equity compensation in the form of restricted stock units and stock options. She was granted 3,796 shares of common stock as annual RSUs and an option for 6,040 shares of common stock.
The RSUs and options are part of the issuer's director compensation program and each RSU represents one share of common stock. Both awards vest in full on the earlier of May 5, 2027 or the date of the next annual meeting of stockholders. Following the RSU grant, she holds 23,715 common shares directly, and the new option has an exercise price of $65.87 per share and expires on May 5, 2036.
HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton received equity compensation awards on May 5, 2026. She was granted 6,796 restricted stock units (RSUs), each representing one share of common stock, and a stock option for 6,040 shares at an exercise price of $65.87 per share.
Both the RSU grant and the option grant will vest in full on the earlier of May 5, 2027 or the date of the company’s next annual meeting of stockholders. Following the RSU award, Connaughton directly holds 45,294 shares of common stock.
Halozyme Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on May 5, 2026. Of 118,474,300 common shares outstanding as of the record date, 104,138,244 shares were represented, meaning a large majority of shareholders participated.
Stockholders elected Bernadette Connaughton and Matthew L. Posard as Class I directors for three-year terms, with each receiving more than a majority of the outstanding shares. They also approved, on an advisory basis, the compensation of the company’s named executive officers and ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton sold 1,625 shares of common stock in an open-market transaction at $63.48 per share. After this sale, she directly holds 38,498 shares. The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance.
Halozyme Therapeutics Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 6,173,547 shares of Common Stock, representing 5.21% of the class as reported for the period ending 03/31/2026. The filing shows sole dispositive power of 6,173,547 shares and sole voting power of 902,329 shares. The filing is signed by Ashley Grim on 04/30/2026.
Halozyme Therapeutics has appointed Darren Snellgrove as Chief Financial Officer, effective June 8, 2026, succeeding interim CFO David Ramsay, who will move to an advisory role during a brief transition. Snellgrove brings more than 30 years of finance leadership, most recently serving as Vice President, Investor Relations and previously as CFO of Johnson & Johnson’s Pharmaceuticals sector.
His compensation includes a $670,000 annual salary, a target bonus equal to 50% of salary (prorated for 2026), and a minimum $4,000,000 long-term incentive award in 2027. Upon joining, he will receive equity awards with a total grant date value of $7,200,000, split between $3,200,000 in restricted stock units that vest over three years and $4,000,000 in stock options vesting over four years under the 2021 Stock Plan, plus a $350,000 sign-on cash bonus subject to partial repayment if he leaves or is terminated for misconduct within 24 months.